Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Lund, Søeren Søgaard ^a   Tarnow, Lise ^a   Astrup, Anne Sofie ^a   Hovind, Peter ^a   Jacobsen, Peter Karl ^a   Alibegovic, Amra Ciric ^a   Parving, Ida ^a   Pietraszek, Lotte ^a   Frandsen, Merete ^a   Rossing, Peter ^a   Parving, Hans Henrik ^b,c   Vaag, Allan Arthur ^a,d  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; AWARENESS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; GYNECOLOGIC DISEASE; HUMAN; HYPOGLYCEMIA; INJURY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTPATIENT CARE; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 54449097429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003363     Document Type: Article

References (33)

1. American Diabetes Association (2006) Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1: S4-42.
2. Devries JH, Snoek FJ, Heine RJ (2004) Persistent poor glycaemic control in adult Type 1 diabetes. A closer look at the problem. Diabetic Medicine 21: 1263-1268.
3. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329: 977-986.
4. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 353: 2643-2653.
5. DeFronzo RA (1982) Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23: 313-319.
6. Hundal RS, Inzucchi SE (2003) Metformin: new understandings, new uses. Drugs 63: 1879-1894.
7. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, et al. (2005) Mefformin monotherapy for type 2 diabetes mellitus. Cochrane database of systematic reviews (Online) 3: 1-117.
8. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 352: 854-865.
9. Lestradet H, Besse J, Billaud L (1960) Study of the action of a biguanide (N,N-dimethylguanylguanidine) on a group of 235 diabetic children. La Presse Medicale 68: 391-393.
10. Ferguson AW, De La Harpe PL, Farquhar JW (1961) Dimethyldiguanide in the treatment of diabetic children. The Lancet pp 1367-1369.
11. Schatz H, Winkler G, Jonatha EM, Pfeiffer EF (1975) Studies on juvenile-type diabetes in children. Assessment of control under treatment with constant and variable doses of insulin with or without addition of biguanides. Diabete & Metabolisme 1: 211-220.
12. Gin H, Slama G, Weissbrodt P, Poynard T, Vexiau P, et al. (1982) Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia 23: 34-36.
13. Pagano G (1983) Mefformin reduces insulin requirement in Type 1 (insulin-dependent) diabetes. Diabetologia 24: 351-354.
14. Coscelli C, Palmari V, Saccardi F, Alpi O, Bonora E (1984) Evidence that metformin addition to insulin induces an amelioration of glycemic profile in type I (insulin-dependent) diabetes mellitus. Current Therapeutic Research 35: 1058-1064.
15. Gin H (1985) Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism, Clinical and Experimental 34: 923-925.
16. Gin H, Freyburger G, Boisseau M, Aubertin J (1989) Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Research and Clinical Practice 6: 61-67.
17. Janssen M, Rillaerts E, De LI (1991) Effect of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomedecine & Pharmacotherapy 45: 363-367.
18. Lacigova S, Rusavy Z, Jankovec Z, Kyselova P (2001) Metformin in the treatment of type 1 diabetics - a placebo controlled study. Casopis Lekaru Ceskych 140: 302-306.
19. Gomez R, Mokhashi MH, Rao J, Vargas A, Compton T, et al. (2002) Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. Journal of Pediatric Endocrinology & Metabolism 15: 1147-1151.
20. Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, et al. (2002) The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 25: 2153-2158.
21. Särnblad S, Kroon M, Aman J (2003) Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. European Journal of Endocrinology 149: 323-329.
22. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D (2003) Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 26: 138-143.
23. Khan AS, McLoughney CR, Ahmed AB (2006) The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. Diabetic Medicine 23: 1079-1084.
24. Moon RJ, Bascombe LA, Holt RI (2007) The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes, Obesity and Metabolism 9: 143-145.
25. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. American Journal of Medicine 103: 491-497.
26. Brown H, Prescott R (2006) Applied Mixed Models in Medicine. West Sussex, UK: John Wiley & Sons, Ltd.
27. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, et al.(2007) Targeting hyperglycaemia with either metformin or repaglinide in-non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obesity and Metabolism 9: 394-407.
28. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, et al. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. New England Journal of Medicine 334: 952-957.
29. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr (1999) Body-mass index and mortality in a prospective cohort of U.S. adults. New England Journal of Medicine 341: 1097-1105.
30. Willett WC, Dietz WH, Colditz GA (1999) Guidelines for healthy weight. New England Journal of Medicine 341: 427-434.
31. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, et al. (2005) Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: A case-control study. The Lancet 366: 1640-1649.
32. Perneger TV (1998) What's wrong with Bonferroni adjustments. British Medical Journal 316: 1236-1238.
33. World Health Organization (1999) Definition, Diagnosis and C, Classification of Diabetes Mellitus and its Complication. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. WHO/NCD/NCS/99.2. pp 1-59.